A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Aug 2026 → Sep 2027
See other at-risk trials from Eli Lilly

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Aug 2026 to Sep 2027
    • Recruitment opened
    • Start date changed from estimate of Sep 2026 to Sep 23, 2026
    • Site details revised at 3 of 3 sites
  2. Primary and study completion dates: Aug 2026 to Sep 2027 Show 4 more changesShow less
    • Start date: Dec 2025 to Sep 2026
    • Study sites: 1 to 3
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 1 entry
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Eli Lilly
366 trials monitored
See 16 trials at risk
The purpose of this study is to test the use of a screening tool to detect changes in the eye that are associated with Alzheimer's disease in adult participants with memory issues. For each participant, the study will last up to one month and requires one visit to the research site.
Trial Details
NCT Number NCT07254234
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Cognitive Dysfunction, Memory Disorders
Related terms Cognitive Dysfunction, Memory Disorders
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov